Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial
2024

Benefit from Dose-Dense Chemotherapy for Breast Cancer

Sample size: 2003 publication 10 minutes Evidence: high

Author Information

Author(s): Matikas Alexios, Papakonstantinou Andri, Loibl Sibylle, Steger Günther G., Untch Michael, Johansson Hemming, Tsiknakis Nikos, Hellström Mats, Greil Richard, Möbus Volker, Gnant Michael, Bergh Jonas, Foukakis Theodoros

Primary Institution: Karolinska Institutet

Hypothesis

Can dose-dense chemotherapy provide significant benefits for patients with high-risk breast cancer compared to standard treatment?

Conclusion

Dose-dense chemotherapy improves outcomes for all patients with primary resected high-risk breast cancer without any subgroup identified that does not benefit.

Supporting Evidence

  • Median follow-up was 10.3 years.
  • Treatment with tDD EC/D improved 10-year BCRFS across all subgroups.
  • Absolute benefit from tDD EC/D was stable across risk-defined subpopulations.
  • PREDICT underestimated overall survival in the entire population and across all subgroups.
  • No differential treatment effect over time was observed.

Takeaway

This study shows that giving chemotherapy more frequently helps breast cancer patients do better, and all patients should consider this treatment.

Methodology

The study was a phase 3 randomized trial comparing tailored dose-dense chemotherapy to standard interval chemotherapy in high-risk breast cancer patients.

Potential Biases

Potential biases due to the open-label nature of the study and the subjective nature of some endpoints.

Limitations

The study's open-label design may have influenced outcomes, and the treatment approach has evolved since the trial was conducted.

Participant Demographics

Women aged 18-65 years with high-risk non-metastatic breast cancer.

Statistical Information

P-Value

0.026

Confidence Interval

95% CI 0.30–0.93

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.lanepe.2024.101162

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication